ENvue Medical, Inc.

ENvue Medical, Inc. is a medical technology company focused on developing intelligent, non-invasive solutions for enteral care in both clinical and home settings. The company's mission is to enhance patient safety and clinical workflow through proprietary technologies that offer real-time guidance, intelligent navigation, and non-invasive therapeutic solutions. Headquartered in Tyler, Texas, ENvue Medical also maintains research and development facilities in Tel-Aviv and Nesher, Israel, with additional offices in Arlington Heights, Illinois.

The company operates primarily through two distinct technology platforms. Its flagship product, the ENvue™ Navigation Platform, is an FDA 510(k)-cleared, minimally invasive electromagnetic navigation system designed to assist clinicians in the accurate placement of feeding tubes into the gastrointestinal tract, providing real-time bedside visualization. ENvue Medical also develops acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology for applications such as pain therapy, biofilm prevention, and wound healing. Additionally, the company offers over-the-counter reusable ENFit syringes.

ENvue Medical, Inc. is publicly traded on NASDAQ under the ticker symbol FEED. The company has recently expanded its U.S. hospital footprint, with its ENvue Navigation Platform commercially deployed across 40 facilities as of April 2026. Recent developments include a Notice of Allowance for a patent on a feeding tube design integrating electromagnetic navigation with a distal-tip camera, and a distribution agreement with U-Deliver for its ENFit syringes. Leadership includes CEO Doron Besser, M.D., and David Johnson, who was appointed Chairman of the Board in late 2025/early 2026. The company is also exploring new applications, such as integrating vibration-based technology to enhance comfort for patients with nasogastric tubes.